Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487184 | 0.88 | MEN1 (0.66) | SMN1; SMN2MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL2098801 | 0.86 | MAPT (0.69) | POLBSMN1; SMN2BRD4MAPTHDAC3 | |
| SCHEMBL30084568 | 0.86 | MAPT (0.69) | POLBSMN1; SMN2BRD4MAPTHDAC3 | |
| SCHEMBL14188875 | 0.81 | MEN1 (0.60) | SMN1; SMN2MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL2009980 | 0.80 | MEN1 (0.72) | POLBSMN1; SMN2BRD4HDAC3HDAC4 | |
| SCHEMBL14292042 | 0.80 | HDAC3 (0.68) | POLBBRD4MAPTHDAC3HDAC4 | |
| SCHEMBL17244586 | 0.77 | HDAC3 (0.64) | POLBSMN1; SMN2BRD4MAPTHDAC3 | |
| SCHEMBL13752250 | 0.77 | HDAC3 (0.64) | POLBSMN1; SMN2BRD4HDAC3HDAC4 | |
| SCHEMBL486592 | 0.77 | POLB (0.65) | POLBSMN1; SMN2MAPTHDAC3HDAC4 | |
| SCHEMBL14426831 | 0.77 | GAA (0.78) | POLBSMN1; SMN2BRD4HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| CN-104666246-A | Orally Bioavailable Lipid-based Constructs | SDG INC AN OHIO CORPRATION | 2015-06-03 | — | — | CN | claimed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | claimed |
| WO-2011022396-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2011-02-24 | — | — | WO | claimed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-7858116-B2 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. (US) | 2010-12-28 | — | — | US | claimed |
| CN-101917971-A | Orally bioavailable lipid-based structures | SDG INC AN OHIO CORP | 2010-12-15 | — | — | CN | claimed |
| EP-2205217-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2010-07-14 | — | — | EP | claimed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | claimed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | claimed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-1087753-A1 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG, Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999059545-A1 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0274467-B1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | GEHO, W., Blair (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | POLB 4282/4885SMN1; SMN2 3997/4885BRD4 1700/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | POLB 4659/4885SMN1; SMN2 3362/4885BRD4 3129/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | POLB 4702/4885SMN1; SMN2 4225/4885BRD4 1380/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | POLB 3957/4885SMN1; SMN2 3866/4885BRD4 3058/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | POLB 4664/4885SMN1; SMN2 3745/4885BRD4 1406/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | POLB 4755/4885SMN1; SMN2 3786/4885BRD4 4537/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | POLB 4685/4885SMN1; SMN2 3217/4885BRD4 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.